Current CardioDX CMO and former Executive Director of AstraZeneca to help advance NewCardio's platform technology
SANTA CLARA, Calif., Dec. 11 /PRNewswire-FirstCall/ --NewCardio, Inc., a cardiac diagnostic and services company, today announced that Philip T. Sager, M.D., FACC, FAHA, FHRS, has joined the Company's Scientific Advisory Board.
Dr. Sager is currently the Chief Medical Officer of CardioDX, a cardiovascular genomic diagnostics company focused on serving cardiologists by offering clinically validated, actionable genomic diagnostics. Prior to joining CardioDx, he was Executive Director at AstraZeneca Inc. where he was responsible for the medical and scientific leadership of several worldwide pharmaceutical development programs and the corporate strategies for QT/CV Safety issues in drug development. Before joining AstraZeneca, Dr. Sager was Medical Director for the Schering-Plough Research Institute where he played key roles in the development and NDA approval of drugs to treat hypercholesterolemia. He joined the pharmaceutical industry after 11 years at the UCLA School of Medicine where he was a tenured faculty member in cardiology. He is a Fellow of the American Heart Association, the American College of Cardiology, and the Heart Rhythm Society. Dr. Sager is Co-Chair of the Scientific Oversight Committee and Executive Committee member of the FDA-sponsored Cardiac Safety Research Consortium and is a member of the International Committee on Harmonization E14 Expert Working Group. Dr. Sager received B.S. degrees from the Massachusetts Institute of Technology, and his M.D. from Yale University, where he also completed medical residency, cardiology fellowship, and a cardiovascular electrophysiology fellowship. He has published more than 150 scientific manuscripts and abstracts.
Branislav Vajdic, PhD, NewCardio's Chief Executive Officer, commented, "Dr. Sager is a recognized leader in the field of Electrophysiology and brings vast knowledge regarding the interests and demands of pharmaceutical customers to our Scientific Advisory Board. His experience in clinical and drug development settings, and his expertise in drug cardiac safety issues, will prove invaluable to NewCardio as we advance our platform technology and build solutions to address a wide range of cardiology issues."
Dr. Sager added, "NewCardio's unique three-dimensional ECG platform promises to be one of the most important innovations to electrocardiology in many decades. This technology has the potential to support a wide-range of solutions, which can save lives, improve quality of care, accelerate drug development and deliver precise, easy-to-understand information. I am excited to participate in this important effort and look forward to contributing to the development of this platform technology."
About NewCardio, Inc.
NewCardio is a cardiac diagnostic and services company focused on the development of a proprietary platform technology to provide higher accuracy to, and increase the value of, the standard 12-lead electrocardiogram (ECG). NewCardio's development-stage software and hardware products and services are intended to improve the diagnosis and monitoring of cardiovascular disease (CVD), as well as cardiac safety assessment of drugs under development. NewCardio's three-dimensional ECG platform is designed to reduce the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. For more information, visit www.newcardio.com.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by management. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K/A (No. 2) for the year ended December 31, 2007 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. We assume no obligation to, and do not currently intend to, update these forward-looking statements.
To join our email distribution please click this link: http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0
CONTACT: Investors, Jeff Stanlis, VP of Communications, +1-602-476-1821,
jeff@haydenir.com, for NewCardio, Inc.
Web site: http://www.newcardio.com/
